Plain-English translation of NCT04861584 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining a drug called toripalimab with two chemotherapy medications (gemcitabine and cisplatin) works better than chemotherapy alone for treating advanced bladder cancer before surgery. You would receive four rounds of the combined treatment over about 12 weeks, then have surgery to remove your bladder and tumor. The goal is to see if adding this new immunotherapy helps shrink tumors and improves survival.
Bladder cancer that has grown into the muscle layer is serious, and surgery alone doesn't always prevent the cancer from coming back. This trial is exploring whether giving this medication along with standard chemotherapy before surgery can help fight the cancer more effectively and improve long-term outcomes.
You likely qualify if…
You likely don't qualify if…
You would come to the hospital or clinic every 3 weeks for about 12 weeks to receive chemotherapy by IV infusion on specific days, along with four doses of the immunotherapy medication. Blood tests and imaging scans would monitor how well the treatment is working. After completing four cycles of treatment, you would have surgery within 6 weeks to remove your bladder and the surrounding tissue. You would also need to provide tumor tissue samples for research and attend follow-up visits to monitor your health after surgery.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Zhujiang Hospital
Enrollment target
~41 participants
Started
June 2021
Primary completion
October 2026
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in December 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Abai Xu, doctor
Zhujiang Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.